A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab
Clinical trial NCT07391670 · RECRUITING
Trial details
- NCT number
- NCT07391670
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-31
- Primary completion
- 2027-08-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.